IONS vs QURE: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IONS and QURE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IONS and QURE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Ionis Pharmaceuticals is a California-based biotechnology company that invented and commercialized antisense technology, a way to design short strands of nucleic acid that silence or modify the RNA behind disease-causing proteins. For decades it operated largely as an R&D and royalty engine, partnering drugs like Spinraza (spinal muscular atrophy, with Biogen) and Wainua (hereditary ATTR polyneuropathy, with AstraZeneca) to larger companies. It now markets around seven medicines and, starting in 2025, launched its first fully owned products, Tryngolza (olezarsen) for familial chylomicronemia syndrome and Dawnzera for hereditary angioedema.

Full IONS guide

uniQure N.V. is a Netherlands-based, Nasdaq-listed clinical-stage biotech developing adeno-associated virus (AAV) gene therapies for serious central-nervous-system and other genetic diseases. Its lead program is AMT-130, a one-time gene therapy for Huntington's disease, delivered surgically into the brain, that met its primary endpoint at three years with roughly 75% slowing of disease progression versus external controls in a Phase I/II study (an updated analysis put the 36-month slowing at about 80% on cUHDRS). The rest of the pipeline is earlier stage: AMT-162 for SOD1 ALS, AMT-260 for refractory mesial temporal lobe epilepsy, and AMT-191 for Fabry disease. The company already validated its platform once by developing Hemgenix, the hemophilia B gene therapy now commercialized by CSL Behring, which produces royalty income.

Full QURE guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• IONS drivers: Owned commercial launches; Olezarsen label expansion.
• QURE drivers: AMT-130 accelerated-approval review; First-mover position in Huntington's.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Ionis still operates at a loss, with 2026 non-GAAP operating loss guidance in the range of roughly $425 million to $475 million, and a trailing-twelve-month net loss of about $565 million, so profitability remains unproven. For QURE, uniQure is a single-asset biotech, so any negative surprise on AMT-130, whether a Complete Response Letter, a request for a controlled confirmatory trial before approval, manufacturing questions, or safety concerns from an invasive brain-delivery procedure, could sharply reduce the company's value.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick IONS if you believe its drivers more; QURE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the IONS and QURE guides.

IONS. Ionis trades as a growth-stage biotech, valued on future product sales rather than current earnings since it remains unprofitable. After a ~46% fall in 2026 the stock sits near 8 times trailing sales, roughly half its value at the start of the year, while revenue has kept beating expectations and Tryngolza has gained its large sHTG label. The 23 analysts tracked have a mean target near $84, and Q3 results on November 4, 2026 (consensus revenue ~$187 million) are the next test of the launch.

QURE. uniQure is pre-profit, so traditional valuation multiples like P/E do not apply and the stock is valued on the probability-weighted potential of AMT-130, which the market sharply marked down after the September 2026 four-year data. Revenue is minimal, mostly Hemgenix royalties and license deals, while losses run near $250 million a year. Analysts' mean target was about $61 across 12 analysts in October 2026, far above the share price, a gap that shows how much depends on the FDA outcome.

Headline figures (approximate, October 2026): IONS shows market cap ~$7.2B (share price ~$43 on Oct 16, 2026), revenue (ttm) ~$874M; 2025 revenue ~$944M, q2 2026 revenue ~$268M (Q1 2026 ~$246M); EPS -$0.42 vs -$0.88 estimate, 2026 revenue Guidance ~$875M-$900M; analyst consensus ~$919M; QURE shows revenue (ttm) ~$18.7 million (Q2 2026 ~$5.1 million, mostly license and royalty), net loss (ttm) ~$252 million (Q2 2026 ~$71 million, EPS ~-$1.07 vs ~-$0.71 expected), cash vs debt ~$810 million cash, ~$552 million debt (June 30, 2026), share price ~$22.07 (October 16, 2026; YTD ~-5.6%, 1 year ~-63%).

IONS and QURE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined IONS and QURE exposure against your real portfolio. It is not an investment adviser.